The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

We analyzed the association between achievement of early complete cytogenetic response (CCyR) and event-free survival (EFS) and overall survival (OS) in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib 400 mg (n = 73), or imatinib 800 mg daily (n = 208),...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jabbour, Elias, Kantarjian, Hagop, O'Brien, Susan, Shan, Jenny, Quintas-Cardama, Alfonso, Faderl, Stefan, Garcia-Manero, Guillermo, Ravandi, Farhad, Rios, Mary Beth, Cortes, Jorge
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2011
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291489/
https://ncbi.nlm.nih.gov/pubmed/21803854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-348110
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky